TCIM
AST

TIAA CREF Investment Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

TIAA CREF Investment Management’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-83,337
Closed -$121K – 3215
2018
Q1 		$121K Hold
83,337
– – ﹤0.01% 3006
2017
Q4 		$188K Buy
83,337
+7,285
+10% +$18.4K ﹤0.01% 3006
2017
Q3 		$259K Buy
76,052
+3,029
+4% +$10.2K ﹤0.01% 3018
2017
Q2 		$259K Buy
73,023
+4,821
+7% +$15.9K ﹤0.01% 3060
2017
Q1 		$232K Sell
68,202
-2,438
-3% -$9.48K ﹤0.01% 2966
2016
Q4 		$325K Sell
70,640
-13,938
-16% -$57.5K ﹤0.01% 2962
2016
Q3 		$359 Hold
84,578
– – ﹤0.01% 2960
2016
Q2 		$203K Buy
84,578
+55,082
+187% +$199K ﹤0.01% 3091
2016
Q1 		$139K Hold
29,496
– – ﹤0.01% 3019
2015
Q4 		$116K Hold
29,496
– – ﹤0.01% 3099
2015
Q3 		$114K Buy
29,496
+25,446
+628% +$117K ﹤0.01% 3069
2015
Q2 		$19K Sell
4,050
-457
-10% -$4.38K ﹤0.01% 3217
2015
Q1 		$30K Hold
4,507
– – ﹤0.01% 3106
2014
Q4 		$15K Buy
+4,507
New +$18.1K ﹤0.01% 3140

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

TIAA CREF Investment Management's AST Position: Q2 2018 in Review

TIAA CREF Investment Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2018, closing a stake of 83,337 shares — an estimated $121K sold.

TIAA CREF Investment Management first reported a position in AST in Q4 2014 and held it in 14 quarters. The position peaked at $325K in Q4 2016. 62 funds tracked by Wall St. Rank hold AST as of Q2 2018.

  • TIAA CREF Investment Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2018 after selling out during the quarter.
  • TIAA CREF Investment Management sold 83,337 Asterias Biotherapeutics Inc. Series A shares in Q2 2018, an estimated $121K.
  • TIAA CREF Investment Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 14 quarters.
  • TIAA CREF Investment Management's Asterias Biotherapeutics Inc. Series A position peaked at $325K in Q4 2016.
  • 62 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2018.

Based on TIAA CREF Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.